section name header

Pronunciation

tye-o-TROPE-ee-yum

Classifications

Therapeutic Classification: bronchodilators

Pharmacologic Classification: anticholinergics

Indications

REMS


Action

  • Acts as anticholinergic by selectively and reversibly inhibiting M3 receptors in smooth muscle of airways.
Therapeutic effects:
  • Decreased incidence and severity of bronchospasm in COPD and asthma.

Pharmacokinetics

Absorption: Handihaler: 19% absorbed following inhalation; Respimat: 33% absorbed following inhalation.

Distribution: Extensive tissue distribution; due to route of administration concentrations occur in lung.

Metabolism/Excretion: 74% excreted unchanged in urine; 25% of absorbed drug is metabolized.

Half-Life: 5–6 days.

Time/Action Profile

(bronchodilation)

ROUTEONSETPEAKDURATION
Inhalnrapid5 min24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: tachycardia

Derm: rash

EENT: glaucoma

GI: dry mouth, constipation

GU: urinary difficulty, urinary retention

Resp: paradoxical bronchospasm

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA)

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Spiriva Handihaler, Spiriva Respimat

Canadian Brand Names

Spiriva

Pill Image

tiotropium-bromide_195-9142.jpg